CalciMedica (NASDAQ:CALC) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Separately, Oppenheimer reaffirmed an outperform rating and set a $14.00 target price on shares of CalciMedica in a report on Monday, April 1st.

CalciMedica Stock Up 25.7 %

Shares of NASDAQ:CALC opened at $3.96 on Thursday. CalciMedica has a 52-week low of $1.75 and a 52-week high of $8.38. The stock has a market cap of $42.57 million, a price-to-earnings ratio of -1.84 and a beta of 1.35. The business has a 50-day moving average price of $5.26 and a 200-day moving average price of $4.61.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07. As a group, equities analysts anticipate that CalciMedica will post -2.05 EPS for the current fiscal year.

Institutional Trading of CalciMedica

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Meritage Portfolio Management grew its holdings in CalciMedica by 360.0% in the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock valued at $132,000 after purchasing an additional 36,000 shares during the period. BML Capital Management LLC grew its holdings in CalciMedica by 63.8% in the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after purchasing an additional 56,643 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new stake in CalciMedica in the third quarter valued at approximately $432,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.